Glucosamine vs. MSM for Dog Joint Pain: Which One Actually Earns a Spot in the Bowl

By Justin Shmalberg, DVM, CVA, ACVN, ACVSMR

✓ Medically reviewed by Justin Shmalberg, DVM, CVA, ACVN, ACVSMR — August 11, 2026 For general education — not a substitute for veterinary care.

Comparisons · August 13, 2026 · 5 min read

Glucosamine and MSM treat joint pain differently, and the evidence for each is not equally strong.

Here’s the fork: if a chew’s label leads with “glucosamine,” you’re looking at a cartilage-support ingredient with a genuinely mixed research record. If it leads with “MSM,” you’re looking at an anti-inflammatory sulfur compound with a thinner but more consistent story in reducing pain signals. Most bags on the shelf contain both, plus chondroitin, so the real decision isn’t “which one” — it’s whether the combination on that label has doses anyone bothered to test.

Start here if you’re short on time: glucosamine’s canine trial data is inconsistent, MSM’s canine-specific trial data is thin, and neither ingredient works fast. Judge a product by whether it discloses milligrams per dose and whether the company can produce a certificate of analysis, not by which acronym is bigger on the bag.

In my practice I saw a nine-year-old Labrador named Biscuit, sixty-eight pounds, whose owner first noticed him hesitating at the bottom of the porch steps in early fall — not refusing them, just pausing a beat longer than he used to before committing to the climb. He’d always jumped straight into the back of the SUV; by October he was waiting for the tailgate lift instead. The owner was weighing cost against a growing pile of supplements she’d already tried, and she was tired of paying for chews Biscuit wouldn’t finish. We talked through what glucosamine and MSM could realistically be expected to do — support cartilage matrix turnover and blunt some inflammatory signaling, respectively — versus what they couldn’t do, which was reverse existing joint damage or replace an NSAID during a flare. That framing, more than any single ingredient, is what actually changes how owners use these supplements.

What glucosamine is actually built to do

Glucosamine is a building block for glycosaminoglycans, the molecules that make up joint cartilage and synovial fluid. The theory is straightforward: supply more raw material, support the cartilage matrix, slow the wear. The trial record is less straightforward. A PubMed: randomised double-blind, positive-controlled trial in dogs with confirmed hip or elbow osteoarthritis found statistically significant improvements in pain, weight-bearing, and severity scores by day 70 for the glucosamine/chondroitin group. That’s a genuine positive result, and it’s the study most glucosamine marketing quietly leans on.

But a newer, larger trial complicates the picture. A Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: prospective, block-randomized, double-blinded, placebo-controlled clinical trial comparing glucosamine/chondroitin against marine-derived fatty acid compounds and carprofen found that, after four weeks, the marine compounds and the NSAID produced significantly greater improvement in objective peak vertical force than either glucosamine/chondroitin or placebo. Glucosamine didn’t separate meaningfully from the placebo group on that objective gait measure. Two well-designed trials, two different verdicts — which is the honest state of the evidence, not a marketing footnote.

Where MSM’s evidence actually comes from

MSM (methylsulfonylmethane) is an organic sulfur compound, and its case rests less on canine-specific trials and more on its documented anti-inflammatory mechanism plus human osteoarthritis data. VCA Animal Hospitals notes MSM is commonly paired with glucosamine and chondroitin in veterinary joint products, functioning as an anti-inflammatory and antioxidant rather than a cartilage building block. The strongest controlled data for MSM’s pain effect comes from human medicine: a Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study: randomized controlled study on MSM supplementation in knee osteoarthritis found meaningful reductions in pain scores over placebo. That’s human evidence, not canine, and it should be cited that way — as a plausible mechanism carried over, not proof of an equivalent effect in dogs.

I still think about an eleven-year-old mixed-breed rescue, closer to fifty pounds, whose owner switched her from a glucosamine-only chew to a combination product after noticing she was sleeping later into the morning before getting up to greet the family — a subtle sign, easy to miss, that stiffness was settling in overnight. We didn’t promise a transformation. What we agreed on was a six-to-eight-week trial window, because neither ingredient acts quickly, and a fair evaluation of a joint supplement means giving it real time before judging it a failure or a win. That patience is the part owners skip most often, and it’s the part that actually determines whether they get useful information out of the trial.

What actually separates a defensible product from a viral one

Neither ingredient works in isolation from formulation quality, and this is where the trend-chasing gets dangerous. Look for:

• Disclosed milligram doses per ingredient, not a proprietary blend that hides how much glucosamine or MSM is actually in each chew.
• NASC membership or third-party lab testing, since animal supplements aren’t FDA-approved drugs and quality control varies by manufacturer.
• A combination formula, since most of the credible canine trial data tests glucosamine alongside chondroitin, not as a solo ingredient, and MSM is typically studied as an add-on rather than standalone.
• Realistic labeling — “may help support joint comfort,” not “clinically proven to reverse arthritis.” If a bag promises a cure, that’s the label overselling ingredients whose own trial data is mixed at best.

For a dog whose main problem is night-time stiffness rather than daytime lameness, the practical differences in how these supplements are dosed and timed matter more than the marketing; our glucosamine guide for dogs struggling with stairs at night goes through that scenario directly. And if you’re trying to figure out how a joint supplement compares against a scored field of competitors rather than just the two headline ingredients, see the BoutiqueTok joint supplement verdict.

The BoutiqueTok verdict

By the time a dog is old enough that owners are Googling glucosamine versus MSM, the honest answer is neither one alone. I’ve watched families spend months debating which single ingredient to buy while skipping the more useful questions: is the dose disclosed, is the company NASC-listed, and has the owner given the product enough time to show anything at all. Glucosamine has the better-documented — if mixed — canine trial history; MSM has a more consistent anti-inflammatory mechanism but thinner dog-specific data. Together, in a properly dosed combination product, they’re a reasonable low-risk addition to a joint-care plan. Alone, either one is a bet with incomplete information behind it. That’s not a viral answer, but it’s the one the evidence actually supports.